---
title: "Targeted Long-Acting HIV PrEP in sub-Saharan Africa: Modeled Impact and Programme Costs to 2050"
id: "medrxiv-2-targeted-deployment-of-long-acting-hiv-pre-exposure-prophylaxis-in-sub-saharan"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-2-targeted-deployment-of-long-acting-hiv-pre-exposure-prophylaxis-in-sub-saharan"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.05.26364769v1?rss=1"
published_at: "2026-10-07T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Targeted Long-Acting HIV PrEP in sub-Saharan Africa: Modeled Impact and Programme Costs to 2050
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-2-targeted-deployment-of-long-acting-hiv-pre-exposure-prophylaxis-in-sub-saharan
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.05.26364769v1?rss=1)
- **Published At:** 2026-10-07T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study uses a deterministic, age-structured compartmental model of HIV among adults aged 15+ across 34 sub-Saharan African countries that account for 98% of adults living with HIV in the region. - Antiretroviral therapy (ART) coverage is assumed to reach **95% by 2030** in all countries modelled. - Long-acting pre-exposure prophylaxis (LAP) is assumed to reduce HIV acquisition by **96%** in the model. - The analysis evaluates allocations of a fixed supply of LAP under different targeting rules: uniform allocation, allocation by district/sex/age, and “perfect” within-group risk identification (upper bound). - Across countries, targeting by district, sex and age averted **2–21 times** as many infections as uniform allocation; perfect within-group risk identification increased that to **5–32 times**. - Multipliers from targeting were largest in low-prevalence countries (where absolute numbers averted were smaller); in higher-burden settings multipliers were **2–6** (district/sex/age) and **5–11** (perfect targeting). - Scenario: 3 million LAP users from 2028 in 11 countries currently receiving Global Fund-supported lenacapavir. Under this, uniform allocation averted ~**41,000** infections by 2050; targeting by district/sex/age averted ~**601,000** (range 360,000–1,660,000); perfect targeting averted ~**972,000** (490,000–3,570,000). - Discounted averted ART costs fully offset LAP costs by 2050 if the full LAP programme cost per person-year is at or below certain thresholds: ~US$50 with perfect risk targeting, US$30 with district/sex/age targeting, and US$2 with uniform allocation. - Expanding LAP to 15 million users by 2035 reduced modelled adult incidence across sub-Saharan Africa to below **0.1 per 1000 person-years** by 2049, about a decade earlier than without LAP, assuming ART reaches 95% by 2030. - The authors conclude that **targeting** determines both public-health impact and net cost-effectiveness of LAP; allocation by district, sex and age is feasible now and substantially multiplies infections averted per person-year of LAP. - The study notes that better identification of highest-risk individuals within demographic groups and sustained use among them could further increase impact. Details on methods and supplementary material are stated to be available in the manuscript and supplementary files.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=0cvxxoRNiQ9sroTyqwTWH1W6RI5Jo4FqsJk_zB.DenE-1791448121.012878-1.2.1.1-DZ8oZZueNpYBfoYvIm1DneZmtC6rmWPY5T5K46RpxDYtA.fq3y5gkWohSVqVe0kH) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.10.05.26364769v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Targeted Deployment of Long-Acting HIV Pre-Exposure Prophylaxis in sub-Saharan Africa: Modelled Impact on Infections and Programme Costs to 2050 [ View ORCID Profile](http://orcid.org/0000-0002-9681-0424)Timothy B Hallett, [ View ORCID Profile](http://orcid.org/0000-0002-4839-2213)Steve Kretschmer, [ View ORCID Profile](http://orcid.org/0000-0002-3609-4526)Mark Dybul doi: https://doi.org/10.64898/2026.10.05.26364769 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Timothy B Hallett 1 Imperial College London; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Timothy%2BB%2BHallett%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hallett%20TB&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATimothy%2BB%2BHallett%2B) * [ORCID record for Timothy B Hallett](http://orcid.org/0000-0002-9681-0424 "Open in new tab") * For correspondence: timothy.hallett@imperial.ac.uk Steve Kretschmer 2 DesireLine, Istanbul, Turkiye; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Steve%2BKretschmer%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kretschmer%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASteve%2BKretschmer%2B) * [ORCID record for Steve Kretschmer](http://orcid.org/0000-0002-4839-2213 "Open in new tab") Mark Dybul 3 Center for Global Health Practice and Impact, Georgetown University, Washington, D.C., USA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mark%2BDybul%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Dybul%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMark%2BDybul%2B) * [ORCID record for Mark Dybul](http://orcid.org/0000-0002-3609-4526 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.10.05.26364769v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1316037/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.10.05.26364769v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1316037/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.10.05.26364769v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1316037/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.10.05.26364769v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1316037/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.10.05.26364769v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1316037/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.10.05.26364769v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1316037/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background Long-acting HIV pre-exposure prophylaxis (LAP) could transform HIV prevention in sub-Saharan Africa, but its public-health impact and value-for-money will depend on whether programmes can reach people at greatest risk. We quantified the potential impact and efficiency of targeted LAP deployment across sub-Saharan Africa. Methods We developed a deterministic, age-structured compartmental model of HIV among adults aged 15 years or older in African countries accounting for 98% of adults living with HIV in sub-Saharan Africa. Antiretroviral therapy (ART) was assumed to reach 95% coverage by 2030 in all countries. LAP was assumed to reduce HIV acquisition by 96%. In model analyses, LAP was allocated according to rules that specify the degree to which programmes can effectively allocate it to those at greatest risk of acquiring HIV, including using a person's district, sex and age-group, and other signals of risk. Findings Across 34 countries, allocating a fixed quantity of LAP by district, sex and age averted 2 - 21 times as many infections as uniform allocation; perfect identification of within-group risk, an upper bound, raised this to 5 - 32 times. Multipliers were largest in low-prevalence countries, where absolute impact was smallest; in higher burden settings, they were 2 - 6 and 5 - 11, respectively. If 3 million people used LAP from 2028 in the 11 countries currently receiving Global Fund-supported lenacapavir, uniform allocation would avert about 41,000 infections by 2050, targeting by district, sex and age about 601,000 (range 360,000 - 1,660,000), and perfect risk targeting about 972,000 (490,000 - 3,570,000). Discounted averted ART costs fully offset LAP costs by 2050 at a total cost of up to ~US$50 per person-year with perfect risk targeting, $30 with targeting by district, sex and age, and $2 with uniform allocation. Expansion to 15 million users by 2035 brought modelled adult incidence across sub-Saharan Africa below 0.1 per 1000 person-years in 2049, about a decade earlier than projected without LAP, under the assumption that ART coverage reaches 95% in every country by 2030. Interpretation Targeting determines both the impact and the net cost of LAP. Allocation by district, sex and age is feasible now and multiplies the infections averted by each person-year of LAP. LAP offsets its cost through averted treatment only when it is targeted and its fully loaded cost is near the low end of current estimates. Better identification of people at highest risk within demographic groups, and sustained use among them, could add substantially to impact. The same approach could guide the allocation of LAP in other settings where HIV risk is concentrated. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present work are contained in the manuscript. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.10.05.26364769v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.10.05.26364793v1 "Machine learning predicts relapse after anti-TNF withdrawal in ulcerative colitis using rectal biopsy transcriptomics")[Next ](https://www.medrxiv.org/content/10.64898/2026.10.05.26364763v1 "Spatial distribution and socioeconomic correlates of anaemia among women of reproductive age in Ghana: a hotspot analysis of the 2022 Demographic and Health Survey") Posted October 07, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.10.05.26364769v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/10/07/2026.10.05.26364769.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.10.05.26364769v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.10.05.26364769v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/10/07/2026.10.05.26364769.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Targeted Deployment of Long-Acting HIV Pre-Exposure Prophylaxis in sub-Saharan Africa: Modelled Impact on Infections and Programme Costs to 2050 Timothy B Hallett, Steve Kretschmer, Mark Dybul medRxiv 2026.10.05.26364769; doi: https://doi.org/10.64898/2026.10.05.26364769 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.05.26364769v1%26text%3DTargeted%2520Deployment%2520of%2520Long-Acting%2520HIV%2520Pre-Exposure%2520Prophylaxis%2520in%2520sub-Saharan%2520Africa%253A%2520Modelled%2520Impact%2520on%2520Infections%2520and%2520Programme%2520Costs%2520to%25202050 "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.05.26364769v1%26t%3DTargeted%2520Deployment%2520of%2520Long-Acting%2520HIV%2520Pre-Exposure%2520Prophylaxis%2520in%2520sub-Saharan%2520Africa%253A%2520Modelled%2520Impact%2520on%2520Infections%2520and%2520Programme%2520Costs%2520to%25202050 "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.05.26364769v1%26title%3DTargeted%2520Deployment%2520of%2520Long-Acting%2520HIV%2520Pre-Exposure%2520Prophylaxis%2520in%2520sub-Saharan%2520Africa%253A%2520Modelled%2520Impact%2520on%2520Infections%2520and%2520Programme%2520Costs%2520to%25202050%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.05.26364769v1%26title%3DTargeted%2520Deployment%2520of%2520Long-Acting%2520HIV%2520Pre-Exposure%2520Prophylaxis%2520in%2520sub-Saharan%2520Africa%253A%2520Modelled%2520Impact%2520on%2520Infections%2520and%2520Programme%2520Costs%2520to%25202050 "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.10.05.26364769v1&count=horizontal&via=&text=Targeted%20Deployment%20of%20Long-Acting%20HIV%20Pre-Exposure%20Prophylaxis%20in%20sub-Saharan%20Africa%3A%20Modelled%20Impact%20on%20Infections%20and%20Programme%20Costs%20to%202050&counturl=www.medrxiv.org/content/10.64898/2026.10.05.26364769v1 "Tweet This") ## Subject Area * [Public and Global Health ](https://www.medrxiv.org/collection/public-and-global-health) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (626) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (914) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (341) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4891) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (486) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (421) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (661) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1648) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16081) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (34) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1220) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7135) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (738) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1077) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5142) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1448) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1797) * [Hematology](https://www.medrxiv.org/collection/hematology) (592) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1356) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16367) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1185) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (679) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (729) * [Neurology](https://www.medrxiv.org/collection/neurology) (7408) * [Nursing](https://www.medrxiv.org/collection/nursing) (371) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1103) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1266) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1012) * [Oncology](https://www.medrxiv.org/collection/oncology) (3667) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1071) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (399) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (460) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (484) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (142) * [Pathology](https://www.medrxiv.org/collection/pathology) (712) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1824) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (741) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (777) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (6005) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9851) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2469) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1481) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1257) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (653) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (788) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (588) * [Surgery](https://www.medrxiv.org/collection/surgery) (786) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (107) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (311) * [Urology](https://www.medrxiv.org/collection/urology) (299) Evaluation/discussion of this paper x Comments 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions and read our [Comment Policy](https://connect.medrxiv.org/news/2022/03/21/commenting_on_preprints) before commenting. The content of a comment is not endorsed by medRxiv. Share this comments tab (click to copy link)Copied! TRiP medRxiv partners with journals and review services to enable posting of peer reviews and editorial decisions related to preprints they are evaluating. Reviews are posted with the consent of the authors. Community Reviews medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors. Automated Evaluations Certain services provide automated analysis of preprints. Analyses invited by the authors are displayed at the top of this tab. Those done independently of authors are shown underneath . None of these analyses is endorsed by medRxiv. Blog/Media Links medRxiv aims to inform readers abo
## Related Clinical Research

- [Self-reported tuberculosis prevalence and vulnerability factors in six rural Indian districts](https://medichelpline.com/clinical-feed/plos-one-16-self-reported-prevalence-of-tuberculosis-and-selected-associated-vulnerability.md)
- [Monocyte phenotypes associated with peri‑coronary inflammation in people with and without HIV](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-distinct-monocyte-phenotypes-are-associated-with-peri-coronary-inflammation-in.md)
- [Augmented Trials Mixing Randomized and Observational Data for Postnatal HIV Prophylaxis](https://medichelpline.com/clinical-feed/medrxiv-1-combining-randomized-and-observational-data-the-case-of-postnatal-prophylaxis.md)
- [Readiness for long-acting injectable HIV treatment and PrEP among Ugandan clinic clients](https://medichelpline.com/clinical-feed/medrxiv-7-readiness-to-start-long-acting-injectable-hiv-treatment-and-prevention-and.md)
- [Reflecting on 50 Years of Interleukin-2: Advancements in Immunotherapy and Retrovirology](https://medichelpline.com/clinical-feed/stat-news-2-opinion-50-years-ago-my-colleagues-and-i-pursued-basic-research-science-that.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.